Discover trends, market shifts, and competitive outlooks for the trulicity global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Anticipated CAGR of the Trulicity Market, and What Factors Will Drive It?

The market size of Trulicity has significantly expanded over the past few years. The increase is projected to rise from $7,320 million in 2024 to $7,980 million in 2025, showing a compound annual growth rate (CAGR) of 9%. The substantial growth during this historic period is tied to several factors, including a surge in obesity rates, an expanding population of diabetic patients, an upswing in pharmaceutical production, the rise of unhealthy lifestyles, the demonstrated efficacy of various therapies, and escalating healthcare spending.

The market size of Trulicity is predicted to witness a robust increase in the coming years, growing to a value of $11,180 million by 2029 with a compound annual growth rate (CAGR) of 8.8%. The anticipated growth within the forecast period can be credited to the rising acceptance of digital health technologies, heightened health consciousness among individuals, expansion of educational and awareness campaigns, an escalating demand for innovative treatments, and enhanced healthcare accessibility. Tech integrations, strategic partnerships, product advancements, an emphasis on tailored medicines, combination therapies, and sustainability initiatives are amongst the major trends for the forecast period.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19941&type=smp

Which Primay Drivers Are Accelerating Growth in the Trulicity Market?

The trulicity market is predicted to be driven forward by the increasing population with diabetes. Diabetes, a chronic medical condition distinguished by high blood sugar levels, occurs due to the body’s inadequate production of insulin or its improper use. Without efficient management, serious complications may ensue. Factors such as urbanization, unhealthy dietary habits, lack of physical activity and genetic susceptibility contribute to the increase in diabetes. This, in turn, amplifies the demand for effective treatments like trulicity, which assists in maintaining blood sugar levels and enhancing patient results. For example, the Office for Health Improvement and Disparities, a government department in the UK, reported in March 2024 that the proportion of people in England with type 1 diabetes who received 8 care processes from participating GP practices in the NDA had increased to 43.8% in March 2023, compared to 35.2% in 2022. Thus, the escalating diabetes prevalence is propelling the expansion of the trulicity market.

Which Primary Segments of the Trulicity Market Are Driving Growth and Industry Transformations?

The trulicitymarket covered in this report is segmented –

1) By Type: Prefilled Syringe Package; Vial Package

2) By Application: Type 2 Diabetes Management; Glycemic Control; Weight Management; Cardiovascular Risk Reduction

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19941&type=smp

Which Regions Are Key Players in the Growth of the Trulicity Market?

North America was the largest region in the trulicity market in 2024. The regions covered in the trulicity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Trulicity Industry Dynamics?

A significant trend in the trulicity market is the drive towards innovation of the trulicity (dulaglutide) drug, particularly in reducing major adverse cardiovascular events. A once-weekly injectable treatment, Trulicity (dulaglutide) is designed to aid blood sugar control in adults diagnosed with type 2 diabetes by imitating the role of the GLP-1 hormone to improve insulin secretion, decelerate gastric emptying, and decrease appetite. In November 2022, US-based pharmaceutical company, Eli Lilly and Company confirmed the US FDA approval of Trulicity (dulaglutide) as a supplement to diet and exercise to enhance glycemic control in adults and children aged 10 years and above with type 2 diabetes mellitus (T2DM). This came as a result of a 26-week randomized, double-blind, placebo-controlled trial with an open-label extension for another 26 weeks, involving 154 pediatric patients aged 10 and older with T2DM.

Strategic Investment Movements within the Trulicity Market to Accommodate Growing Demand

The principal trend in the trulicity market is integrating strategic investment strategies like biologics production facilities to attain a competitive edge and accommodate the increasing demand. Biologics production facilities denote specialized manufacturing plants designed to manufacture biologic drugs, complex treatments derived from living organisms, including monoclonal antibodies, vaccines, and cell and gene therapies. For example, in January 2023, Eli Lilly and Company, a US-based pharmaceutical company, pledged $450 million to expand its manufacturing plant in North Carolina, thus improving the production of its diabetes drug Trulicity. This is in addition to a $1.7 billion investment in the facility, which anticipates beginning operation later this year, completed fully by 2027, and responsible for an additional 100 jobs. Further, Lilly is also establishing two new facilities in Indiana, and is investing €400 million into biologics production in Ireland. In entirety, the company estimates an expenditure of $2.5 billion on manufacturing capacity over the next few years to meet the growing demand and facilitate the launch of new products.

View the full report here:

https://www.thebusinessresearchcompany.com/report/trulicity-global-market-report

What Parameters Are Used to Define the Trulicity Market?

Trulicity is a prescription medication that contains the active ingredient dulaglutide, which is a GLP-1 (glucagon-like peptide-1) receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes, often in combination with other medications. It is administered as a once-weekly injection and may also help with weight loss and reducing the risk of cardiovascular events.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19941

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model